Literature DB >> 29732531

Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease: A British Society for Haematology Guideline.

Amrana Qureshi1, Banu Kaya2, Shivan Pancham3, Russell Keenan4, Jeremy Anderson5, Magbor Akanni6, Jo Howard7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29732531     DOI： 10.1111/bjh.15235

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  17 in total

1.  Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort.

Authors:  Robert O Opoka; Heather A Hume; Teresa S Latham; Adam Lane; Olatundun Williams; Jennifer Tymon; Maria Nakafeero; Phillip Kasirye; Christopher M Ndugwa; Chandy C John; Russell E Ware
Journal:  Haematologica       Date:  2019-10-24       Impact factor: 9.941

2.  Optimal disease management and health monitoring in adults with sickle cell disease.

Authors:  Jo Howard; Swee Lay Thein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

3.  Sickle cell disease: an update.

Authors:  Emma Conway O'Brien; Sahla Ali; Timothy Chevassut
Journal:  Clin Med (Lond)       Date:  2022-05       Impact factor: 5.410

Review 4.  Considerations for Selecting Cognitive Endpoints and Psychological Patient-Reported Outcomes for Clinical Trials in Pediatric Patients With Sickle Cell Disease.

Authors:  Anna M Hood; Lori E Crosby; Hanne Stotesbury; Melanie Kölbel; Fenella J Kirkham
Journal:  Front Neurol       Date:  2022-06-21       Impact factor: 4.086

5.  KNOWLEDGE, ATTITUDE AND USE OF HYDROXUYREA AMONG ADULT SICKLE CELL DISEASE PATIENTS.

Authors:  O Sonubi; T R Kotila
Journal:  Ann Ib Postgrad Med       Date:  2019-12

Review 6.  Clinical management of sickle cell liver disease in children and young adults.

Authors:  Eirini Kyrana; David Rees; Florence Lacaille; Emer Fitzpatrick; Mark Davenport; Nigel Heaton; Sue Height; Marianne Samyn; Fulvio Mavilio; Valentine Brousse; Abid Suddle; Subarna Chakravorty; Anita Verma; Girish Gupte; Marki Velangi; Baba Inusa; Emma Drasar; Nedim Hadzic; Tassos Grammatikopoulos; Jonathan Hind; Maesha Deheragoda; Maria Sellars; Anil Dhawan
Journal:  Arch Dis Child       Date:  2020-11-11       Impact factor: 3.791

Review 7.  Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings.

Authors:  Baba Psalm Duniya Inusa; Atoyebi Wale; Abdul Aziz Hassan; Tushar Idhate; Livingstone Dogara; Ifeoma Ijei; Yewen Qin; Kofi Anie; Juliana Olufunke Lawson; Lewis Hsu
Journal:  F1000Res       Date:  2018-09-04

Review 8.  Rational Drug Design of Peptide-Based Therapies for Sickle Cell Disease.

Authors:  Olujide O Olubiyi; Maryam O Olagunju; Birgit Strodel
Journal:  Molecules       Date:  2019-12-12       Impact factor: 4.411

Review 9.  Research in Sickle Cell Disease: From Bedside to Bench to Bedside.

Authors:  Gabriel Salinas Cisneros; Swee Lay Thein
Journal:  Hemasphere       Date:  2021-06-01

Review 10.  Effective use of hydroxyurea for sickle cell anemia in low-resource countries.

Authors:  Alexandra Power-Hays; Russell E Ware
Journal:  Curr Opin Hematol       Date:  2020-05       Impact factor: 3.218
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.